Safety and efficacy outcomes of acute ischemic stroke patients treated using telestroke vs. in-person assessments at a comprehensive stroke centre during the COVID-19 pandemic

Thank you for presenting this interesting innovation study showing how a change in utilization of a known tool has the potential to improve efficiency in the management of stroke without changes in efficacy or safety outcomes. I was wondering if you could elaborate more on: a) possible challenges that the broader application of this tool could bring and how to address them, b)whether the patients treated by telehealth were different at baseline (e.g., severity of disease). Additionally, which other conditions do you think could potentially benefit from using similar tools?